Two drug companies that are leading the race to develop coronavirus vaccines bowed to public pressure on Thursday, abandoning their traditional secrecy and releasing comprehensive road maps of how they are evaluating their vaccines.

The companies, Moderna and Pfizer, revealed details about how participants are being selected and monitored, the conditions under which the trials could be stopped early if there were problems, and the evidence researchers will use to determine whether people who got the vaccines were protected from Covid-19.

Moderna’s study will involve 30,000 participants, and Pfizer’s 44,000.

WHO Europe chief urges nations to keep up virus quarantines GENEVA (AP) — The World Health Organization’s European director warned national governments Thursday against reducing the quarantine period for people potentially exposed to the coronavirus, even... AP NEWS

GENEVA (AP) — The World Health Organization’s European director warned national governments Thursday against reducing the quarantine period for people potentially exposed to the coronavirus, even as he acknowledged that COVID-19 “fatigue” was setting in with growing public resistance to the measures needed to control the pandemic.

Global coronavirus cases surpass 30 million: Reuters tally Global coronavirus cases exceeded 30 million on Thursday, according to a Reuters tally, with the pandemic showing no signs of slowing. Jane Wardell U.S.

(Reuters) - Global coronavirus cases exceeded 30 million on Thursday, according to a Reuters tally, with the pandemic showing no signs of slowing.

Eli Lilly reports first, promising results for an antibody against COVID-19 More results expected soon from similar trials Science | AAAS

Today brings the first whisper of success for a class of closely watched drugs that it’s hoped will begin to beat back COVID-19 before vaccines are licensed: monoclonal antibodies, engineered versions of the same virus-fighting antibodies that the body naturally produces.